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Role of Leukocytes in Hemostasis During 
Orthotopic Liver Transplantation 
HANNO RIESS, M.D., MARIANNE JOCHUM, M.D., 
WERNER MACHLEIDT, M.D., GABRIELE HIMMELREICH, M.D., 
WOLF OTTO BECHSTEIN, M.D., MARTIN MUSER, 
PETER NEUHAUS, M.D., ROLF ROISSANT, M.D., and DIETER HUHN, M.D. 
For a long time, there has been clear evidence from 
clinical and experimental data supporting a pivotal role of 
different types of leukocytes in hemostasis . 1 - 4 This is 
particularly true for coagulopathies in sepsis, promyelo-
cy te leukemia, and endotoxemia. In addition to leuko-
cyte-derived tissue factor, mediators released from poly-
morphonuclear ( P M N ) granulocytes and macrophages 
may contribute to platelet activation, endothelial dam-
age, and coagulopathy. Some of these mediators are 
more or less characterized, and in addition to their own 
biologic role in hemostatsis, they can be used as indica-
tors for other mediators released in response to the same 
stimulus. 
Tumor necrosis factor-a ( T N F ) , an antitumor cytok-
ine produced by activated monocytes and macrophages 
as well as by T lymphocytes, 5 promotes the adherence o f 
granulocytes and monocytes to endothelium and induces 
tissue factor synthesis in monocytes and endothelial 
cells/ ' In orthotopic liver transplantation ( O L T ) , T N F 
rises precede the clinical manifestations o f allograft re-
j e c t i o n , 7 X and first-week T N F levels are thought to be 
useful predictors of long-term graft outcome. 7 Further-
more, recent studies have proposed a role for T N F in 
disseminated intravascular coagulation (D1C) . 9 
From the Departments of Internal Medicine, Surgery, and Anes-
thesiology, Universitätsklinikum Rudolf Virchow, Berlin, and the De-
partment of Clinical Chemistry and Biochemistry and Department of 
Physiological Chemistry, Innenstadtklinik der Universität, München. 
Germany. 
Reprint requests: Prof. Dr. Riess, Medizinische Klinik and Polik-
linik, Augustenburger Platz 1, D-1000 Berlin 65. Germany 
Neopterin, a pyrazino-pyrimidine compound, plays 
an important role in the biosynthesis of serotonin and 
catecholamines. 1 0 It is released from monocytes and 
macrophages on s t imulat ion," but its biologic signifi-
cance is only poorly understood. Serum levels o f neop-
terin increased significantly 24 hours after T N F was ad-
ministered to six healthy volunteers, " and neopterin 
augmented the increase in gamma-interferon-, l i -
popolysaccharide-, or interleukin-2-induced T N F pro-
duction by macrophages and peripheral blood mononu-
clear ce l l s . 1 4 
The cysteine proteinase cathepsin B is released 
from lysosomes of macrophages and the serine protein-
ase elastase from lysosomes of P M N granulocytes on 
activation. Both substances are believed to be impor-
tant nonspecific mediators of inflammation. 1 Further-
more, we could prove their appearance in the graft liver 
perfusate. l h We suggested a causal relation between the 
extracellular release of these mediators immediately after 
graft revascularization and the disseminated intravascular 
consumption coagulopathy observed in the reperfusion 
phase of O L T . Bleeding complications, which become 
apparent predominantly in the reperfusion phase , 1 7 - 1 9 
thus—at least in part—may be triggered by leukocytic 
mediators. 
First investigations in O L T confirm our clinical im-
pression 2" that aprotinin, a proteinase inhibitor known to 
decrease blood transfusion requirements in cardiac sur-
ge ry . 2 1 also reduces the bleeding tendency in O L T . 1 8 " 2 2 
Therefore, we investigated the effect of two different 
aprotinin regimens, instituted in order to control hyperfi-
brinolysis, on the release o f phagocyte proteinases and on 
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some measures of hemostasis during O L T and extended 
our previous studies to T N F and neopterin. 
PATIENTS AND METHODS 
Patients 
In an open and randomized study, we investigated 
23 patients with terminal liver disease (Table 1) who 
underwent their first O L T at the University Hospital Ru-
dolf Virchow, Berlin, Germany. Thirteen patients were 
randomly allocated to a bolus regimen of 3 x 0.5 mi l l ion 
kallikrein inhibitor units ( K I U ) of aprotinin and 10 to a 
continuous aprotinin infusion starting with a dose o f 
200,000 KIU/hour with the induction of anesthesia in-
creasing to 400,000 KIU/hour with the onset of the anhe-
patic phase until skin closure. 2 2 Heparin was started not 
earlier than at the end of the operation with 250 IU/hour 
and increased to 500 IU/hour 12 hours later. In the sec-
ond part o f the study, the samples of the 10 patients 
receiving the aprotinin infusion were analysed for T N F 
and neopterin. 
The O L T was carried out by established surgical 
techniques using a venovenous bypass. 2 3 Packed red 
blood cells (RBC) and fresh frozen plasma (FFP), but 
neither platelets nor concentrates of hemostatic factors, 
were administered to compensate for intraoperative and 
postoperative blood loss. Beizer UW-CSS solution (Du 
Pont, Paris, France) was used during cold storage o f the 
graft liver. Blood samples were taken from an arterial 
line after induction of anesthesia and before the start o f 
surgery (sample 1) and 5 minutes before (sample 2) and 
10 minutes after (sample 3) the beginning o f the anhe-
patic stage. Further samples were collected 5 minutes 
before reperfusion (number 4) and 5 minutes (number 5) , 
15 minutes (number 6) , 1 hour (number 7) , and 12 hours 
(number 8) afterwards. In addition, a sample o f the per-
fusate released from the liver graft vein during the flush-
ing w i th arterial blood was taken prior to opening o f the 
hepatocaval anastomosis (sample P). Blood samples 
were collected in plastic syringes prefilled wi th 1/10 vol-
ume of trisodium citrate. 
Methods 
Fibrinogen was estimated by a clott ing assay ac-
cording to Clauss 2 4 and plasminogen by a chromogenic 
substrate method relatively insensitive to aprotinin in the 
diluted sample (Behringwerke, Marburg, Germany). 
Thrombin-ant i thrombin I I I complexes ( T A T ) , elastase in 
complex wi th proteinase inhibitor (EPI) . and plasmin-
antiplasmin complexes (PAP) were determined by 
ELISA (Behringwerke; E. Merck , Darmstadt, Germany; 
and Technoclone, Vienna, Austria; respectively). The 
same was true for ap ro t in in . 2 5 Cathepsin B was measured 
by its enzymatic activity against the aminopeptidase sub-
strate Z-Phe-Arg-N-Mec . 1 5 Neopterin was estimated by 
RIA (Henning, Ber l in , Germany) and T N F by I R M A 
(Medgenix Diagnostics, Fleurus, Belgium). 
Wi lcoxon rank-sum test and two-sample test were 
used to test the significance o f differences wi th in and 
between groups. P values o f < 0 . 0 5 and < 0 . 0 1 were 
considered to be significant and highly significant, re-
spectively. 
TABLE 1. Characteristics of Patients.. Surgical Time, and 
Cold Storage Time of Graft Liver 
Bolus 
Group 
Infusion 
Group 
No. 13 10 
Age 47(40-65) 53 (24-65) 
Male/female 5/8 4/6 
Diagnosis 
Postnecrotic cirrhosis 5 8 
Alcoholic cirrhosis 4 0 
Primary biliary cirrhosis 1 1 
Secondary biliary cirrhosis 1 0 
Budd-Chiari syndrome 1 0 
Hepatocellular carcinoma 1 0 
Metastasis to liver 0 1 
Surgery time (min) 510 (300-610) 540 (310-670) p = 0.14 
Cold storage time (hours) 8(5.5-12.2) 11.2 (5.3-18) p = 0.08 
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Results 
Aprotinin concentrations increased steadily in the 
infusion group ( I ) , reaching maxima at 5 to 60 minutes 
after reperfusion (Fig. 1). In the bolus group ( B ) , plasma 
concentrations o f aprotinin decreased until the beginning 
of the anhepatic phase. Thereafter, they increased, reach-
ing maximal levels between 5 and 60 minutes after re-
vascularization. W i t h the exception o f the init ial blood 
sample, the concentrations of aprotinin were always sig-
nificantly higher in the I group. 
In both groups plasma levels o f EPI rose slowly unti l 
the end of the anhepatic phase, then increased signifi-
cantly to maximal values at 60 minutes (sample 7) after 
revascularization. Thereafter, concentrations o f EPI de-
creased but remained significantly above the baseline. 
The EPI levels were higher in the I group, but the differ-
ences did not reach significance at each timepoint (Fig. 
2). Concentrations in the perfusate were significantly 
higher than in the systemic circulation 5 minutes before 
reperfusion (Table 2; Fig . 3) . 
The activities o f cathepsin B did not change in either 
group until revascularization had been performed. There-
after, levels increased (p < 0.005), wi th maxima at 5 
minutes after reperfusion and gradually returned to the 
pre-reperfusion range until the end of the observation 
period. Cathepsin B concentrations tended to be higher in 
the B group, with differences being significant in the 
anhepatic phase (samples 3 and 4) and 12 hours (sample 
8) after reperfusion (Fig. 4) . Levels in the perfusate were 
significantly higher than in corresponding samples from 
the systemic circulation (see Table 2 and Fig. 3). 
The concentrations of T A T remained relatively low 
until the beginning o f the reperfusion phase, when they 
peaked (p < 0.05) 15 to 60 minutes after revasculariza-
tion in both groups. The T A T levels were significantly 
higher in the I group before and after the beginning o f the 
anhepatic phase (samples 2 and 3) as well as after graft 
perfusion (Fig. 5) . The T A T levels tended to be higher in 
the perfusate (0.1 > p > 0.05, than in the systemic 
blood (see Fig. 3). 
From the beginning of the study period until 15 
minutes after revascularization (sample 6), fibrinogen 
levels were higher in the B group. In both groups, there 
was a significant decrease in fibrinogen after reperfusion 
(Fig. 5) . Plasma levels were higher than those in the 
perfusate (see Fig. 3). 
Plasmin-antiplasmin complex levels rose signifi-
cantly during the anhepatic phase and reached maxima 5 
minutes before and 5 minutes after reperfusion in the I 
and B groups, respectively. Thereafter, the concentrations 
APROTININ PLASMA LEVELS 
K I U / M L 
1 2 3 4 5 6 7 8 
FIG. 1. Concentrations of Aprotinin Applied as Bolus (B) or by Infusion (I) during Liver Transplantation. * = p < 0.01; B vs I. 
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ELASTASE PROTEINASE INHIBITOR COMPLEX 
ng/ml 
FIG. 2. Median Concentrations of Elastase in Complex with Alpha,-Proteinase Inhibitor (EPI) during Liver Transplantation in 
Patients with Aprotinin Application as Bolus (B) or by Infusion (I). * = p < 0.01; B vs I. 
returned to the preanhepatic range. There were no differ-
ences between the groups except for higher PAP levels in 
sample 8 from the I group after reperfusion (Fig. 6). 
In the preanhepatic and early anhepatic phases, plas-
minogen levels were significantly higher in the B group, 
but thereafter, a statistically significant plasminogen 
drop could be seen during the late anhepatic and early 
reperfusion phases in the B group but not in the I group 
(Fig. 6). Plasminogen levels in the perfusate were 
slightly lower than those in the plasma (data not shown). 
In contrast to the plasma levels o f some factors investi-
gated, there were no significant differences in graft per-
fusate levels between the two groups (see Table 2), al-
though there was a trend toward higher EPI levels in the 
infusion group. 
Discussion 
In our previous investigations dealing with the 
changes in hemostasis during O L T , ( ' we postulated that 
the extracellular release of lysosomal proteinases from 
macrophages (cathepsin B) and P M N granulocytes 
(elastase) play an important role in the intravascular acti-
vation and consumption of coagulation factors, leading to 
a DIC-l ike constellation during the reperfusion phase. On 
the other hand, recent experiences of our g r o u p l 8 _ < sug-
TABLE 2. Hemostasis Factors in Graft Liver Perfusate (Median and Range) 
According to Form of Aprotinin Application 
Bolus Group IB) Infusion Group II) p (B vs 1) 
Fibrinogen (g/l) 1.5 (0-2.2) 1.5 (0-2.6) 0.48 
Plasminogen (%) 43 (3-77) 50 (35-87) 0.29 
TAT (ng/ml) 93.2 (40.5-324.2) 73.5(32.5-1500) 0.29 
PAP (ng/ml) 61.4 (29-120) 57.7 (34-93) 0.49 
EPI (ng/ml) 637 (136-904) 912 (399-1396) 0.09 
Cathepsin B (U/l) 34710 (7032-142695) 22191 (967-524265) 0.40 
EPI = elastase-alpha proteinase inhibitor complex, PAP = plasmin-antiplasmin complex, TAT = thrombin-
antithrombin 111 complex. 
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Perfusate versus systemic blood 
EPI Cathepsin B TAT Fbg PAP Pig TNF neopter in 
H H plasma Bill per fusa t 
FIG. 3. Perfusate (P) and Plasma Levels (immediately Before Reperfusion [Sample 4]) of Factors in 10 Patients Undergoing OLT. 
Elastase (EPI, x 100 ng/ml), cathepsin B ( m l l / l ) , t h r o m b i n - a n t i t h r o m b i n III complexes (TAT, ng/ml) , f ibr inogen (Fbg, g/l), plasm i n -
antiplasmin complexes (PAP, ng/ml), p lasminogen (PLG, % ) , t umor necrosis factor (TNF, pg/ml) , and neopterin ( x 1 0 nmol/ l) . 
* = p < 0.05; P vs 4. 
gest a beneficial effect o f aprotinin bolus application in 
reducing signs of hyperfibinolysis and bleeding compli-
cations in patients undergoing OLT. Aprotinin (Trasylol), 
a parenterally applied proteinase inhibitor from bovine 
lung, inhibits plasmin, kall ikrein, trypsin, and, to a much 
lesser extent, urokinase. 2 6 Its toxicity is low, and even 
high doses are well to le ra ted . 2 6 ' 2 7 Continuous infusion of 
aprotinin in higher doses during O L T clearly diminished 
hyperfibrinolysis compared with bolus application and 
resulted in a lower blood product requirement. 2 2 Here, 
we report the effect o f these two different regimens of 
aprotinin application on the levels o f the extracellularly 
released phagocyte proteinases, elastase and cathepsin B , 
in plasma and perfusate of patients undergoing O L T . The 
larger amounts of aprotinin applied in the I group resulted 
in higher plasma levels of the proteinase inhibitor during 
O L T without adverse effects. 
Although not significant at each timepoint, the 
higher concentrations o f EPI, and the reduced levels of 
cathepsin B, in the I group compared with the B group 
are difficult to interpret at first glance. They may be the 
reflection o f differential effects of aprotinin on the activa-
tion of P M N granulocytes and macrophages. More 
l ikely, however, the higher plasma levels o f EPI in the I 
group reflect some imbalance between the groups (Table 
1): more than half of the patients in the I group had severe 
hepatic failure with a strongly impaired capacity to syn-
thesize coagulation factors. This may be responsible, 
too, for the lower starting levels o f fibrinogen and plas-
minogen in the I group. In addition, the surgical proce-
dures lasted longer in the I group because o f prolonged 
preparation in the preanhepatic phase. Thus, the elevated 
plasma levels of EPI in these patients may reflect a preex-
isting increase in inflammatory activity and the enhanced 
release o f elastase by P M N granulocytes entering the 
operative f i e l d . 2 8 Moreover, the graft livers transplanted 
in the I group had longer cold storage times than those 
implanted in the B group, which w i l l result in more 
ischemic cellular damage and increase the inflammation 
response of P M N granulocytes in the graft after revascu-
larization. This interpretation is in accordance with the 
larger amount of EPI released in the perfusate o f the I 
group compared with the B group (see Table 2). 
The same reasons may account for the higher T A T 
levels in the I group. Similar to the increase of EPI and 
cathepsin B , plasma levels o f T A T rose until 60 minutes 
after graft revascularization, whereas fibrinogen levels 
decreased in the reperfusion phase, suggesting prothrom-
bin activation. 
Plasma levels of cathepsin B were higher in the B 
group during the anhepatic phase and at the end of the 
study period. The reasons for this are obscure. There are 
some hints that aprotinin has a stabilizing effect on some 
cell and lysosomal membranes . 2 9 ' 3 0 Thus, it could be that 
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CATHEPSIN B 
1 0 0 0 
8 0 0 H 
6 0 0 H 
4 0 0 
2 0 0 
B I 
anhepa t i c phase 
2 3 4 5 6 7 8 
FIG. 4. Activities of Cathepsin B (Median) during Liver Transplantation when Aprotinin w a s Given as Bolus (B) or by Infusion (I). 
* = p < 0.05; B vs I . 
THROMBIN ANTITHROMBIN III AND FIBRINOGEN 
3 0 0 
2 5 0 
2 0 0 
1 5 0 
1 0 0 1 
-
n g / m 
-*- T A T ( B ) 
T A T (1) 
- B - F B G ( B ) 
F B G (1) 
anhepat i c phase 
0 , 5 
2 3 4 5 6 7 8 
FIG. 5. Median Concentrations of Thrombin-Antithrombin III Complex (TAT) and Fibrinogen (Fbg) during Liver Transplantation 
when Aprotinin w a s Given as Bolus (B) or by Infusion (I). * = p < 0.05; B vs I. 
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PLASMINOGEN AND PLASMIN ANTIPLASMIN 
n g / m l (PAP) anhepa t i c phase % (p ig ) 
FIG. 6. Median Concentrations of Plasmin-Antiplasmin Complex (PAP) and Plasminogen (Pig) during Liver Transplantation 
when Aprotintin w a s Given as Bolus (B) or by Infusion (I). * = p < 0.05; B vs I . 
higher levels o f aprotinin inhibited cathepsin B release 
from the patients' macrophages during O L T . This effect 
w i l l be masked by the massive influx o f cathepsin B 
originating from the (aprotinin-free) graft l iver in the 
early reperfusion phase and may become evident again 
12 hours after revascularization. It may be speculated, 
too, that higher levels o f aprotinin w i l l diminish the stim-
ulation o f macrophages by reducing fibrinolysis-derived 
protein degradation products. 
We and others demonstrated an inhibit ion o f (hyper) 
fibrinolysis in O L T by aprotinin, • resulting in a de-
crease in the activity o f tissue-type plasminogen activator 
and an increase in whole blood lysis t ime. 1 * This is in 
agreement with the fact that plasminogen levels clearly 
decreased during the anhepatic and early reperfusion 
phases in the B group but not in the I group. They did so 
despite the fact that aprotinin levels o f 100 K I U / m l or 
higher added to normal plasma in vitro resulted in a 
decrease of measured plasminogen in the test system 
used (data not shown). In addition. PAP levels, reflecting 
plasminogen activation, seemed to be somewhat higher 
in the B group. Therefore, circulating plasmin in the 
infusion group may be inhibited, not only by alpha 2 -
antiplasmin, which is clearly reduced in all the patients 
(data not shown), but also, and to a higher degree, by 
26 12 
aprotinin. ' 
Thus, higher aprotinin levels shift the hemostatic 
balance toward a state o f hypercoagulability by reducing 
plasminogen activation without clear evidence o f a re-
duction in the extracellular release of phagocyte protein-
ases during O L T . However, clinically, no signs of intra-
vascular fibrin formation with consequent organ 
dysfunctions became evident. A l l 23 patients are alive, 
with two women, one in each group, receiving another 
allograft months after the primary OLTs. Nevertheless, 
as patients undergoing O L T usually have acquired A T I I I 
def ic iency, 1 8 substitution therapy with A T I I I (and mini-
dose heparin) at the end of the anhepatic phase may be 
considered when aprotinin is given. 
EFFECTS ON TNF AND NEOPTERIN 
Results 
Levels of T N F remained unchanged during the pre-
anhepatic and anhepatic phases (Fig. 7). Wi th revascular-
ization of the graft liver, a highly significant and sus-
tained increase was seen, with maximal values 12 hours 
after reperfusion. The T N F concentration in the perfusate 
did not differ from that in the systemic circulation 5 
minutes before reperfusion (see Fig. 3). 
The concentration of neopterin showed no changes 
during the pre-revascularization phases o f O L T (Fig. 8) 
and increased significantly with reperfusion of the graft, 
wi th maximal values 5 minutes after revascularization 
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TUMOR NECROSIS FACTOR 
35 
30 
25 
20 
15 
5 -
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0 
anhepat ic phase 
1 2 3 4 5 6 7 
FIG. 7. Plasma Levels of TNF during Liver Transplantation. * = p < 0.05; vs sample 4. 
8 
followed by a significant decrease with a minimum I 
hour after reperfusion and a second increase with maxi-
mal values 11 hours later. The median levels measured in 
the perfusate reached more than 15 times those in the 
systemic circulation before reperfusion, a difference that 
was highly significant (see Fig. 3). 
Significant correlations became apparent at different 
time points during O L T between T N F , neopterin. 
elastase, and cathepsin B . most of them after reperfusion 
(Table 3). Furthermore, significant correlations could be 
observed between levels o f T A T and the leukocytic me-
diators. Only cathepsin B and T A T complexes did not 
correlate during O L T . Aprotinin levels showed no corre-
lation with most o f the factors investigated. However, 
there may be a relation between neopterin and aprotinin 5 
minutes after reperfusion (p = 0.098). With regard to the 
perfusate levels, a significant correlation was observed 
between T N F and neopterin and between T A T com-
plexes and elastase. 
Discussion 
The clearly elevated neopterin and cathepsin B lev-
els in the perfusate, together with the increases in sys-
temic levels immediately after graft reperfusion. suggest 
neopterin and cathepsin B release when arterial blood 
passes through the vascular bed of the graft liver. This 
was paralleled by a less pronounced elevation of elastase 
and T A T complexes in the perfusate. However, in the 
perfusate, T A T complexes and elastase correlated signif-
icantly in accordance with an elastase-mediated pro-
thrombin activation in the graft liver and an independent 
increase of neopterin and cathepsin B. These results are 
consistent with our hypothesis that P M N granulocytes 
entering the ischemic and cold-stored liver graft become 
stimulated and that released elastase plays a role in pro-
thrombin activation. Indeed, very preliminary observa-
tions suggest the existence o f noncomplexed elastase in 
some of our perfusate samples. On the other hand, the 
excessive amounts of cathepsin B and the amounts of 
neopterin in the perfusate more likely reflected release 
from the graft rather than stimulation of leukocytes enter-
ing the graft with reperfusion. The exact cellular origin 
of these two mediators seems to be different. Whereas 
cathepsin B is more than 400 times as abundant in the 
perfusate as in the systemic blood samples, this factor is 
about 15 for neopterin. Most l ikely , this difference is 
attributable to the fact that in addition to macrophages, 
hepatocytes altered during cold storage may release 
cathepsin B. In the systemic circulation, the different 
leukocytic mediators—cathepsin B , elastase, T N F . and 
neopterin—as well as the indicator o f thrombin genera-
tion. T A T , increased after revascularization o f the graft. 
There seems to be an interdependence o f these factors 
expressed by the correlations observed. These results are 
an argument for a strong relation between leukocyte acti-
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FIG. 8. Plasma Levels of Neopterin during Liver Transplantation. 
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p < 0.05 vs sample 4. 
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vation and increased thrombin generation with revascu-
larization o f the liver graft. Only cathepsin B did not 
correlate wi th neopterin and T A T complexes, suggest-
ing, again, different origins for these phagocytic media-
tors and a minor role o f cathepsin B in prothrombin 
activation. 
The DIC- l ike state observed in the reperfusion 
phase, 1 7 the phase where bleeding occurs, may in part 
be initiated by leukocyte activation. The decrease in 
platelet count and platelet aggregability observed in the 
reperfusion phase 3 4 may also be initiated by leukocytic 
mediators. However, even i f reperfusion of the graft liver 
is initiating the release o f leukocytic mediators, the vas-
cular bed of the patient's systemic circulation seems to be 
of greater impor tance . 3 ' ' ' 3 6 This may be reflected by cor-
relations weaker in the graft liver's perfusate and stronger 
in the systemic circulation. 
As levels of T N F and neopterin increase in parallel 
with reperfusion of the graft and perfusate levels of neop-
trin are much higher than in the systemic circulation—a 
difference not seen with TNF—the high neopterin levels 
do not seem to be induced by a TNF-mcdiated 1 3 but— 
more l ikely—by a direct activation of monocytes. On the 
other hand, monocytes activated by T N F may contribute 
to the high levels of neopterin in the perfusate and in the 
postreperfusional systemic blood samples. 
Furthermore, the rise in T N F during the reperfusion 
phase may play a role in the increase in plasminogen 
activator inhibitor that is regularly observed after graft 
revascularization, 1 7 ' " ' 3 I thus potentially shifting the he-
T A B L E 3. Correlations between Cathepsin B, TNF, Elastase (EPI), Neopterin, and 
Thrombin-Antithrombin III Complexes (TAT) in Systemic Blood During OLT. The 
samples w i th signif icant (p < 0.05) correlat ions are shown. 
TAT TNF Cathepsin B EPI Neopterin 
TAT 3, 5, 6, 7 none oc
 
5, 6, 7 
TNF 3, 5. 6, 7 none 3, 8 5, 6. 7 
Cathepsin B None None 4, 8 None 
EPI 6. X 3, 8 4. X 8 
Neopterin 5 5, 6. 7 none 8 
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mostatic balance toward hypercoagulability. Another 
prothrombogenic effect of leukocytic mediators may be 
the degradation of endothelial thrombomodulin by cathe-
psin B 3 7 leading to impaired protein C activation. 
The reasons oozing occured in the reperfusion phase 
of O L T in spite of these and other data that seem to 
indicate a prothrombogenic shift after graft revascular-
ization are obscure. First of a l l , it must be kept in mind 
and emphasized that measuring parameters of hemostasis 
in samples of systemic blood hardly reflect what goes on 
in the operative field but at best give an overall summary 
of the patient's hemostasis potential. Thus, the wel l -
accepted enhanced thrombin generation in the first hour 
after reperfusion may stimulate plug-related secondary 
fibrinolysis masked by the increase of PAI in the sys-
temic circulation. In addition to a stimulating effect o f 
leukocytic mediators on PAI release, T N F may stimulate 
the endothelial release of plasminogen proactivators. 3 8 
Indeed, in our patients, we observed an increase in uroki-
nase in the reperfusion phase. 1 8 Cathepsin B , boosting in 
the early reperfusion phase, degrades not only thrombo-
modu l in 3 7 but also extracellular matrix proteins such as 
collagen, laminin, and f ibronect in . 3 ' ' ' 4 0 This proteinase 
may thereby be involved in the disintegration o f unstable 
plugs formed during the anhepatic phase, when plasmin 
generation is clearly increased and coagulation Factor 
X I I I is low. Similarly, elastase is able to degrade fibrin 
present in these plugs and may injure endothelial 
c e l l s . 4 1 ' 4 2 Elastase impairs platelet func t ion , 4 3 and de-
creased platelet aggregability after revascularization has 
been demonstrated. 4 4 
In addition to the actions of individual mediators 
released, interactions between different leukocytic prod-
ucts have to be postulated, such as the inactivation of 
human cystatin, an inhibitor of cathepsin B, by human 
neutrophil elastase.4'' Furthermore, the serine protease 
elastase is an example of the possibility of opposite ef-
fects of a given mediator on the different systems of 
hemostasis. 4 7 ' 4 8 The relative importance o f the various 
reactions probably depends on the local environment: 
e.g., physical factors such as pH and the concentration of 
cofactors and inhibitors. Thus, it is not possible confi-
dently to evaluate the net result on local hemostasis by 
the determination of given factors in samples of systemic 
blood. Furthermore, the leukocytic factors estimated are 
indicators for other leukocytic mediators released in par-
allel from lysosomes and other sources that may interfere 
with hemostasis. 
Recently, it was demonstrated that elevated T N F 
levels up to 100 pg/ml at the end of surgery may be 
indicative of graft rejection within 10 days after O L T . 7 In 
our patients, no graft rejection occurred postoperatively, 
and in only two patients were T N F levels higher than 100 
pg/ml measured at the end of the operation. 
CONCLUSION 
We demonstrated that a release o f mediators from 
different subpopulations of leukocytes takes place during 
O L T . Taking the time course of the elastase complex 
(EPI) into account, there seems to be progressive stimu-
lation of P M N granulocytes during the preanhepatic and 
anhepatic phases followed by massive activation after 
reperfusion. These data are in accordance wi th the role of 
P M N granulocytes in abdominal surgery and poly-
trauma. 1 '^" 8 On the other hand, mediators thought to be 
released primarily from macrophages and monocytes 
showed a significant increase only after reperfusion. For 
cathepsin B and neopterin. perfusate levels were signifi-
cantly higher than the levels in plasma, suggesting re-
lease from the graft. Cathepsin B may originate from 
hepatocytes and macrophages of the graft, less probably 
from monocytes entering the graft during reperfu-
s i o n . 1 5 ' 3 3 Neopterin, on the other hand, probably is re-
leased from macrophages of the graft damaged during 
cold storage. This could account for the first postreperfu-
sional peak of neopterin. The second neopterin peak 
more likely reflects the immune response o f the host to 
the liver graft. This view is supported by the rise in T N F 
after graft revascularization, as T N F production is aug-
mented by neopterin. 1 4 and T N F stimulates neopterin 
release. 1 3 
Aprotinin is believed to reduce bleeding complica-
tions and blood product requirements in O L T . 1 8 " " ' 2 2 
most likely because of its antifibrinolytic properties. In 
addition, aprotinin, even when given only to the recipient 
of the graft, may have a beneficial effect on graft tunc 
t ion 4 ' ' by stabilizing lysosomal membranes. 3 0 By this 
mechanism, higher levels of aprotinin may inhibit the 
release of lysosomal proteinases such as elastase or 
cathepsin B, a hypothesis not clearly disproved by our 
results. 
The prothrombogenic effects o f these leukocytic 
mediators may play an important role in the enhanced 
thrombin generation reflected by increases in T A T , fibrin 
monomers, and D-dimers as well as decreases in fibrino-
gen, A T I I I , and C, inhibitor (see Fig. 4). 1 7 - 1 9 During 
reperfusion, the proteolytic activities o f leukocytic medi-
ators released may be of relevance for bleeding complica-
tions, but this remains very speculative, as the patho-
physiology of oozing after revascularization is still 
poorly understood. 
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